Literature DB >> 12797384

Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae isolated in four southern European countries (ARISE project) from adult patients: results from the cefditoren surveillance program.

F Soriano1, J J Granizo, A Fenoll, M Gracia, R Fernández-Roblas, J Esteban, I Gadea, P Coronel, M Gimeno, E Ródenas, F Santos.   

Abstract

From four southern European countries (Spain, Italy, Portugal, and Greece) 877 Streptococcus pneumoniae isolates were recovered from adult patients with respiratory tract infections between September 2000 and March 2001. The antimicrobial susceptibility to 11 antibiotics was determined in a central laboratory. Penicillin resistance was high in Greece (47.1%) and Spain (25.1%) but much lower in Portugal (7.9%) and Italy (4.8%). On the other hand, erythromycin resistance was high in Italy (38.5%) and Spain (36.2%) with no statistical difference with Greece (29.4%) but reaching significance (p <0.01) with Portugal (15.7%). Resistance to levofloxacin was low (1.5%) but present in Spanish and Italian isolates. Cefditoren, a new cephem antibiotic tested, was the most potent compound (MIC90 = 0.5 microg/ml) followed by levofloxacin and cefotaxime (MIC90 = 1 microg/ml). Given the high rates of penicillin and macrolide resistance reported, there is an evident need for new drugs and continued antimicrobial surveillance of S. pneumoniae.

Entities:  

Mesh:

Year:  2003        PMID: 12797384     DOI: 10.1179/joc.2003.15.2.107

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  6 in total

1.  Clinical and bacteriological efficacy in treatment of acute exacerbations of chronic bronchitis with cefditoren-pivoxil versus cefuroxime-axetil.

Authors:  Jose-Luis Alvarez-Sala; Peter Kardos; Jesús Martínez-Beltrán; Pilar Coronel; Lorenzo Aguilar
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

Review 2.  Cefditoren pivoxil: a review of its use in the treatment of bacterial infections.

Authors:  Keri Wellington; Monique P Curran
Journal:  Drugs       Date:  2004       Impact factor: 9.546

3.  Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid.

Authors:  Thomas P Lodise; Martina Kinzig-Schippers; George L Drusano; Ulrich Loos; Friedrich Vogel; Jürgen Bulitta; Markus Hinder; Fritz Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2007-05-07       Impact factor: 5.191

4.  Crystal structure of cefditoren complexed with Streptococcus pneumoniae penicillin-binding protein 2X: structural basis for its high antimicrobial activity.

Authors:  Mototsugu Yamada; Takashi Watanabe; Takako Miyara; Nobuyoshi Baba; Jun Saito; Yasuo Takeuchi; Fukuichi Ohsawa
Journal:  Antimicrob Agents Chemother       Date:  2007-08-27       Impact factor: 5.191

Review 5.  Cefditoren in upper and lower community-acquired respiratory tract infections.

Authors:  Francisco Soriano; María-José Giménez; Lorenzo Aguilar
Journal:  Drug Des Devel Ther       Date:  2011-02-09       Impact factor: 4.162

6.  A Comparison of Cefditoren Pivoxil 8-12 mg/kg/day and Cefditoren Pivoxil 16-20 mg/kg/day in Treatment of Children With Acute Presumed Bacterial Rhinosinusitis: A Prospective, Randomized, Investigator-Blinded, Parallel-Group Study.

Authors:  Orapan Poachanukoon; Auchara Tangsathapornpong; Sermkiat Tanuchit
Journal:  Clin Exp Otorhinolaryngol       Date:  2015-05-13       Impact factor: 3.372

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.